Compare FRO & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRO | TFX |
|---|---|---|
| Founded | 1985 | 1943 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.6B |
| IPO Year | N/A | N/A |
| Metric | FRO | TFX |
|---|---|---|
| Price | $29.37 | $108.42 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 10 |
| Target Price | $30.33 | ★ $137.11 |
| AVG Volume (30 Days) | ★ 3.2M | 1.2M |
| Earning Date | 02-27-2026 | 02-26-2026 |
| Dividend Yield | ★ 6.36% | 1.28% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | $1,766,241,000.00 | ★ $3,189,988,000.00 |
| Revenue This Year | N/A | $9.60 |
| Revenue Next Year | $19.16 | $10.36 |
| P/E Ratio | $28.65 | ★ N/A |
| Revenue Growth | N/A | ★ 5.42 |
| 52 Week Low | $12.40 | $100.18 |
| 52 Week High | $29.04 | $180.58 |
| Indicator | FRO | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 67.16 | 43.95 |
| Support Level | $27.60 | $101.65 |
| Resistance Level | $29.04 | $107.16 |
| Average True Range (ATR) | 0.79 | 2.76 |
| MACD | 0.06 | 0.73 |
| Stochastic Oscillator | 82.00 | 82.10 |
Frontline PLC is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.